Cost-per-responder analysis for eltrombopag and rituximab in the treatment of primary immune thrombocytopenia in Spain

• मुख्य लेखकों: Eduardo Anguita (लेखक), Francisco Javier Parrondo García (लेखक), José Ramón González-Porras (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Elsevier, 2020-11-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Objective: Splenectomy, thrombopoietin receptor agonists and rituximab are the second-line treatments for steroid-resistant adult primary immune thrombocytopenia. The last two are becoming the most widely used treatments to avoid splenectomy adverse effects and inconveniences. However, the choice be...